MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF- Inhibitor MYMD-1 in SarcopeniaAge-Related Frailty
| MYMDDelisted Stock | USD 1.82 0.02 1.09% |
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
MyMD |
BALTIMORE, July 31, 2023 MyMD Pharmaceuticals, Inc. , a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced statistically significant positive topline results from its randomized Phase 2 study of oral TNF- inhibitor, MYMD-1 in patients with chronic inflammation associated with sarcopenia, or age-related frailty. The study met its primary endpoint
Read at finance.yahoo.com
 |
MyMD Pharmaceuticals Fundamental Analysis
We analyze MyMD Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MyMD Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MyMD Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
MyMD Pharmaceuticals is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
MyMD Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MyMD Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of MyMD Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
MyMD Pharmaceuticals Related Equities
| UBX | Unity Biotechnology | 4.17 | ||||
| RXRX | Recursion Pharmaceuticals | 3.58 | ||||
| GOVX | GeoVax Labs | 2.26 | ||||
| DSGN | Design Therapeutics | 2.25 | ||||
| BOLT | Bolt Biotherapeutics | 2.00 | ||||
| KZR | Kezar Life | 1.86 | ||||
| NVCT | Nuvectis Pharma | 1.53 | ||||
| XBIO | Xenetic Biosciences | 1.47 | ||||
| REPL | Replimune | 1.30 | ||||
| LYRA | Lyra Therapeutics | 1.18 | ||||
| REVB | Revelation Biosciences | 0.33 | ||||
| AVIR | Atea Pharmaceuticals | 0.31 | ||||
| PASG | Passage Bio | 0.15 | ||||
| SRZN | Surrozen | 0.08 | ||||
| NBY | NovaBay Pharmaceuticals | 0 | ||||
| LGND | Ligand Pharmaceuticals | 0.37 | ||||
| KRON | Kronos Bio | 1.04 | ||||
| LYEL | Lyell Immunopharma | 1.61 | ||||
| ORIC | Oric Pharmaceuticals | 1.68 | ||||
| GOSS | Gossamer Bio | 2.33 | ||||
| KROS | Keros Therapeutics | 2.39 | ||||
| LRMR | Larimar Therapeutics | 4.55 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |